Preclinical Pharmacology Studies for Rare Lung Diseases
From early discovery to regulatory submission, Protheragen offers end-to-end non-clinical development solutions to help you reduce program risk, accelerate progress and optimize decision-making. With our deep scientific expertise, cutting-edge technology and global regulatory insight in rare lung diseases, we are confident that we can work with scientists in the field of rare lung disease research around the globe to overcome the challenges of treating rare lung diseases.
Current Status of Development of Drugs for Rare Lung Diseases
The development of drugs for rare lung diseases is undergoing a rapid development phase, with several new drugs in clinical trials or approval worldwide. For example, ATYR-1923 is being developed for the treatment of rare pulmonary diseases (RPIC) with an immune component, including interstitial lung diseases. Global investment in rare lung disease therapeutics is increasing, yet rare disease drug discovery and development still faces many challenges and requires collaboration and sustained investment to achieve more breakthroughs.
Figure 1. The life cycle of SARS-CoV-2 is shown. (Saha RP, et al., 2020) Our Services
Protheragen is an organization focused on providing a full range of research services to scientists in the field of rare lung disease research. We deeply understand the challenges faced by researchers in the drug discovery and development process. For this reason, we are committed to providing advanced pharmacological testing services and comprehensive bioanalytical solutions to help scientists find new treatments for rare lung diseases faster and more effectively.
| Our types of services | Details of our services |
|---|---|
| In vitro biological analysis | We offer a wide range of in vitro assays for assessing the biological activity, mechanism of action and toxicity of compounds. We also offer off-the-shelf assays using commercial kits and in-house developed assays using customized reagent sets. |
| In vivo pharmacologic analysis | We design in vivo studies according to your needs, providing reliable proof-of-concept data to help you understand the efficacy and safety of your drug candidates in relevant animal models. At the same time, our in vivo pharmacology analysis service will provide a comprehensive assessment of the characteristics and drug mechanism in the context of rare lung diseases. |
| Bioanalytical services | We provide accurate and reliable bioanalytical services for quantification of drug levels and metabolites in biological matrices. We have extensive experience with a variety of biological matrices (e.g., serum, plasma, blood, and saliva) from both animals and humans. |
| Medicinal chemistry services | Our medicinal chemistry team works closely with you to hit finding, hit-to-lead, lead optimization, and solve drug discovery challenges. |
| DMPK/ADME | Our Drug Metabolism and Pharmacokinetics (DMPK) and Absorption, Distribution, Metabolism and Excretion (ADME) studies are designed to optimize the pharmacokinetic properties of compounds and guide dosage selection and formulation development. |
Our Core Strengths
- Professional pharmacology testing services. With advanced experimental platforms and rich experience, we are able to accurately predict the biological effects of new therapeutic entities and provide reliable data support for drug discovery and development in rare lung diseases.
- Powerful bioanalytical capabilities. We provide a full range of bioanalytical services from genes to proteins, and from cells to animal models, helping scientists gain a deeper understanding of the mechanisms of rare lung diseases and screen potential drug targets.
- Customized solutions. We understand that every research project is unique, so we provide customized research solutions and technical support according to the specific needs of our clients to ensure that they receive the highest quality service.
Reference
- Saha RP, Sharma AR, Singh MK, et al. Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19. Front Pharmacol. 2020;11:1258.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.